Fore Biotherapeutics is a startup based in All, most recent round Series C+, 3 tracked investors.
Fore Biotherapeutics is a company founded in 2017 headquartered in All. Its most recent tracked round is Series C+. Brouky records 3 investors associated with the company.
Fore Biotherapeutics is a virtual biotechnology company developing plixorafenib, a next-generation BRAF inhibitor designed to target a broad range of BRAF alterations in advanced solid tumors. The company is advancing plixorafenib in the global FORTE Phase 2 registration-intended clinical trial.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.